Medtech company Implantica AG (XSTO: IMP A SDBB) on Wednesday announced the finalisation of its five-year CE mark study results for the RefluxStop device, designed to treat acid reflux, a condition affecting approximately one billion people globally. This milestone precedes the Module 2 submission of the premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA).
The upcoming Module 2, slated for submission this autumn, will include clinical and usability data, as well as findings from a Human Factors Validation Study conducted with 16 foregut/reflux surgeons in Chicago. Responses to FDA feedback from Module 1 will accompany this submission, ensuring compliance with rigorous FDA standards.
Preliminary results from the CE mark study are promising. Contrast swallow x-rays at five years show the RefluxStop device functioning correctly, with no dislocations, migrations or re-herniations. Additionally, 24-hour pH monitoring indicates high satisfaction among participants, with only one subject reporting a failed pH test. In contrast, a competitor's FDA trial reported a 42% failure rate in similar tests at one year.
RefluxStop distinguishes itself by addressing the underlying causes of gastroesophageal reflux disease (GORD) without applying pressure to the esophagus. This innovative approach aims to restore the natural function of the lower esophageal sphincter, potentially revolutionising anti-reflux surgery.
Implantica is committed to integrating advanced technology into medical solutions and has developed a diverse, patent-protected pipeline, including an eHealth platform for monitoring health parameters and a wireless energising platform for powering implants.
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Viatris reports positive results for EFFEXOR in GAD treatment in Japan
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
Conformal Medical reports start of GLACE study
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study